• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

    8/25/25 8:00:00 AM ET
    $IMRX
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email

    - Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer –

    CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor, olomorasib (LY3537982). The supply agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase 2 clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy. In February 2025, Immuneering announced a clinical trial agreement with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with the anti-PD-1 therapy Libtayo® (cemiplimab) in patients with advanced non-small cell lung cancer.

    "This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC," said E.B. Brakewood Chief Business Officer of Immuneering.

    "The combination of atebimetinib and olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway, which is supported by preclinical studies of this combination in which enhanced tumor regression, delayed emergence of tumor resistance and prolonged survival relative to monotherapy was observed. This dual targeted approach has the potential to improve outcomes in a population with limited effective treatment options," said Igor Matushansky, MD, PhD, Chief Medical Officer of Immuneering.

    Immuneering will maintain global development and commercialization rights to atebimetinib.

    About Immuneering Corporation

    Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering's lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company's development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

    Forward-Looking Statements

    This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: our plans to develop, manufacture and commercialize our product candidates; the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including in advanced non-small cell lung cancer; the treatment potential of our pipeline product candidates in other types of cancer; the plans and objectives of Company management for future operations, including with respect to the timing, planning and execution of enrollment, and additional atebimetinib combination trials.

    These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

    These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Media Contact for Immuneering:

    Gina Nugent

    [email protected] 

    Investor Contact for Immuneering:

    Laurence Watts

    619-916-7620

    [email protected] 



    Primary Logo

    Get the next $IMRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRX
    $LLY

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    9/17/2025$830.00Buy → Hold
    Berenberg
    Eli Lilly and Company
    $LLY
    8/27/2025$700.00Reduce → Hold
    HSBC Securities
    Eli Lilly and Company
    $LLY
    8/18/2025$700.00Outperform → Neutral
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    8/7/2025$715.00Outperform → Market Perform
    Leerink Partners
    Eli Lilly and Company
    $LLY
    6/5/2025Buy → Hold
    Erste Group
    Eli Lilly and Company
    $LLY
    4/28/2025$1150.00 → $700.00Buy → Reduce
    HSBC Securities
    Eli Lilly and Company
    $LLY
    4/22/2025$975.00Overweight
    Cantor Fitzgerald
    Immuneering Corporation
    $IMRX
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $IMRX
    $LLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinberg Peter bought $35,900 worth of shares (5,000 units at $7.18), increasing direct ownership by 4% to 141,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/30/25 9:00:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

    New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines  Gateway Labs model provides flexible lab space and tailored scientific engagement to support early-stage biotechs INDIANAPOLIS, Sept. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to support early-stage biotechnology companies by providing lab space and opportunities to collaborate with Lilly scientists. The new facility, developed by and operated in partnership with Alexandria Real Estate Equities, Inc., is

    9/26/25 8:30:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease

    Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. "Kisunla demonst

    9/25/25 6:39:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    SEC Filings

    View All

    SEC Form 424B5 filed by Immuneering Corporation

    424B5 - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:26:30 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:23:28 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Immuneering Corporation

    FWP - Immuneering Corp (0001790340) (Subject)

    9/25/25 6:01:41 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by Berenberg with a new price target

    Berenberg downgraded Eli Lilly from Buy to Hold and set a new price target of $830.00

    9/17/25 7:55:15 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Eli Lilly from Reduce to Hold and set a new price target of $700.00

    8/27/25 8:16:34 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Eli Lilly from Outperform to Neutral and set a new price target of $700.00

    8/18/25 8:49:16 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Feinberg Peter bought $35,900 worth of shares (5,000 units at $7.18), increasing direct ownership by 4% to 141,766 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    9/30/25 9:00:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lilly Endowment Inc sold $18,058,643 worth of shares (23,665 units at $763.10), decreasing direct ownership by 0.02% to 95,606,687 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    9/22/25 4:00:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lilly Endowment Inc sold $81,531,959 worth of shares (106,626 units at $764.65), decreasing direct ownership by 0.11% to 95,630,352 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    9/19/25 4:00:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    Leadership Updates

    Live Leadership Updates

    View All

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anne White to Retire as Executive Vice President and President, Lilly Neuroscience

    INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh

    8/20/25 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New AI Rollouts Signal Shift From Hype to Healthcare Reality

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b

    6/24/25 9:45:00 AM ET
    $LLY
    $PHG
    $PLTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Electronics
    Computer Software: Prepackaged Software

    $IMRX
    $LLY
    Financials

    Live finance-specific insights

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcita

    9/24/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

    - Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025. Th

    9/10/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    $LLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care